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reporting a retrospective study of 108 patients with Candida species bloodstream infections at a hospital in northern Taiwan. In that study, they concluded that the outcome of candidemia was poor, with mortality of 44.3% and 29.8% in C. albicans and non-albicans candidemia, respectively. Although these findings of candidemia are interesting, non-Candida fungal bloodstream infections also deserve research. Therefore, we performed this study to investigate the clinical significance of non-Candida isolates causing fungemia.
The database of the Microbiology Laboratory of Chi Mei Medical Center, Liouying branch, was searched for blood cultures positive for non-Candida fungi from January 2005 to December 2010. The clinical charts of all patients included in this study were retrospectively reviewed. Information was collected on age, gender, and underlying During the study period, a total of 967 specimens from 428 patients had positive blood cultures for fungus. Based on the number of patients with fungemia, the most prevalent species were Candida spp. (n Z 407, 95.1%), followed by Cryptococcus spp. (n Z 12, 2.8%), Trichosporon spp. (n Z 5, 1.2%), Fusarium spp. (n Z 2, 0.5%), Rhodotorula spp. (n Z 1, 0.2%), and Penicillium spp. (n Z 1, 0.2%). After reviewing the associated history, true non-Candida spp. fungemia was confirmed in 16 patients, and transient fungemia due to non-Candida species was diagnosed in five patients. The clinical features of 16 patients with non-Candida species bloodstream infections are summarized in Table 1 . The mean AE standard deviation age was 63.5 AE 12.6 years, and most of the patients (n Z 15, 93.8%) had underlying diseases. Cancer was the most common underlying disease (solid cancer, n Z 7; hematological cancer, n Z 4). Diabetes mellitus and liver cirrhosis were the second most common underlying diseases, follow by HIV infection (n Z 2). Although the antifungal treatments were various, in-hospital mortality developed in more than half of the patients.
In the present work, there were several significant findings. First, Candida spp. remains the most common fungal agent causing bloodstream infection, consistent with previous studies. 2, 3 Second, most of the patients with fungemia due to non-Candida species had underlying immunocompromised conditions, especially cancer. This suggests that physicians should keep alert to these invasive fungal infections in this era of a growing population of immunosuppressed patients. 4 Third, among 12 patients with cryptococcemia, the mortality was as high as 75%, which may be attributed to two reasons: diagnosis of cryptococcemia was not made before four patients die; and most of the patients in this series had cancer.
This retrospective study had two notable limitations. Because of the rarity of these unusual fungal infections, the number of the patients was small and may not be generalized to other hospital in Taiwan. Additionally, we did not perform molecular identification and the in vitro susceptibility to antifungal agents. Both of these deficits still need further large-scale study with advanced laboratory methods.
In conclusion, although non-Candida fungemia is a rare clinical entity, it can develop in immunocompromised patients, and result in poor outcome.
